NEW
YORK, May 14, 2024 /PRNewswire/ -- The
global drug discovery outsourcing
market size is estimated to grow by USD 1.79 bn from 2024-2028, according to
Technavio. The market is estimated to grow at a CAGR of
7.44% during the forecast period.
For more insights on the forecast market size and
historic data (2018 - 2022) - Download
Free sample report in a minutes
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Product
(Small-molecules and Biologics), End-user (Big pharmaceutical
companies, Small and medium-sized pharmaceutical companies, and
Generic pharmaceutical companies), and Geography (North America,
Europe, Asia, and Rest of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
Aragen Life Sciences
Pvt. Ltd., Aurigene Discovery Technologies, Catalent Inc., Charles
River Laboratories International Inc., Curia Global Inc., Domainex,
Eurofins Scientific SE, Evotec SE, GenScript Biotech Corp.,
LABORATORY CORPORATION OF AMERICA HOLDINGS, Lonza Group Ltd., Lupin
Ltd., Novotech Health Holdings, Oncodesign Services, PerkinElmer
Inc, QIAGEN NV, Shanghai Medicilon Inc., Syngene International
Ltd., Thermo Fisher Scientific Inc., and WuXi AppTec Co.
Ltd.
|
Key Market Trends Fueling Growth
Technological innovations significantly impact the drug
discovery outsourcing market by enhancing efficiency, compressing
timelines, and fostering inventive methods. High-Throughput
Screening (HTS) technologies, such as automated platforms,
robotics, and advanced assay techniques, enable the swift screening
of vast compound libraries to identify potential drug candidates
with desired biological activities. Computational biology and
bioinformatics tools are utilized to analyze biological data, model
systems, and predict drug-target interactions. Partners proficient
in computational biology employ techniques like molecular modeling,
molecular dynamics simulations, and structure-based drug design to
expedite hit identification, lead optimization, and rational drug
design initiatives. Key therapeutic areas include genetic,
metabolic, and chronic disorders, as well as diabetes, cancer,
malaria, cardiovascular disorders, cystic fibrosis, multiple
sclerosis, tuberculosis, and various systemic conditions.
Technologies employed include mass spectrometers, chromatographs,
electrophoresis systems, microscopes, image recognition, and drug
design tools.
Market Challenges
The global drug discovery outsourcing market faces challenges
due to the lack of integration and transparency in the supply chain
process.
* Fast delivery services are essential for certain medicines, such
as specialty injections and vaccines, to maintain their
efficacy.
* A centralized system is necessary for tracking inventory changes
and order shipments to ensure efficient distribution.
* Redirection of shipments or distribution vehicles to areas of
high demand can optimize the pharmaceutical supply chain.
* Data from all stages of the supply chain must be incorporated to
effectively track orders and delivery rates.
* Planning and organization can eliminate disruptions and delays,
making the supply chain responsive to unmet medical needs.
* Lack of integration can result in lost time, money, and labor
investments in drug discovery and development processes.
* Delays in delivery can create mistrust among investors and hinder
market growth during the forecast period.
* Complex drug discovery processes necessitate the need for
comprehensive supply chain data management.
* Effective integration and transparency in the supply chain can
lead to improved efficiency, reduced costs, and increased investor
confidence.
Research report provides comprehensive data on
impact of trend, driver and challenges - Buy
Report
Segment Overview
This drug discovery outsourcing market report extensively covers
market segmentation by
- Product
- 1.1 Small-molecules
- 1.2 Biologics
- End-user
- 2.1 Big pharmaceutical companies
- 2.2 Small and medium-sized pharmaceutical companies
- 2.3 Generic pharmaceutical companies
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Small-molecules- In the pharmaceuticals
industry, market segmentation by product plays a significant role
in drug discovery and outsourcing. Pharmacology and biotechnology
are key areas of focus, with small molecules and biologics as
primary product categories. Small molecules, organic compounds
under 900 Daltons, are produced through chemical reactions and are
used to treat genetic disorders, metabolic disorders, and chronic
conditions. Drug discovery involves various techniques such as
artificial intelligence, genomics, proteomics, and High-Throughput
Screening (HTS), utilizing tools like mass spectrometers,
chromatographs, and electrophoresis systems. Disease areas of
interest include diabetes, cancer, malaria, cardiovascular
disorders, cystic fibrosis, multiple sclerosis, tuberculosis, and
various target identification and screening methods for the
respiratory system, pain and anesthesia, oncology, ophthalmology,
hematology, endocrine, gastrointestinal, immunomodulation,
anti-infective, cardiovascular, central nervous system,
dermatology, genitourinary system, and Biologics. These segments
undergo continuous innovation, with advancements in molecular
modeling, drug design, and image recognition.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2018 - 2022) - Download a Sample Report
Research Analysis
The Drug Discovery Outsourcing Market encompasses various
aspects of pharmaceuticals and biotechnology, including drug
discovery for genetic, metabolic, and chronic disorders. This
market caters to the development of Biologics, with a significant
focus on Oncology and Heart disease. Preclinical development is a
crucial phase, involving cell line development, upstream &
downstream processes, and analytical/bioanalytical methods.
In-house medication discovery relies on novel drug therapies for
autoimmune disorders and infectious diseases. External specialized
partners are often engaged to ensure the success of drug
development projects, contributing to the growth of the Drug
Discovery Outsourcing Market.
Market Research Overview
The Drug Discovery Outsourcing Market refers to the contractual
agreement between pharmaceutical and biotechnology companies and
external service providers for the research and development of new
drugs. This market is driven by the high cost and time-consuming
nature of in-house drug discovery, as well as the need for
specialized expertise and technologies. The market caters to
various stages of drug discovery, including target identification,
lead optimization, preclinical testing, and clinical trials. The
outsourcing of drug discovery also enables companies to focus on
their core competencies and reduce risks associated with drug
development. The global Drug Discovery Outsourcing Market is
expected to grow significantly due to the increasing number of
collaborations and partnerships between industry players and CROs
(Contract Research Organizations). The market is segmented based on
the type of service, stage of drug discovery, and geography.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Product
-
- Small-molecules
- Biologics
- End-user
-
- Big Pharmaceutical Companies
- Small And Medium-sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/drug-discovery-outsourcing-market-size-is-set-to-grow-by-usd-1-79-bn-from-2024-2028--robust-demand-for-biosimilars-to-boost-the-market-growth-technavio-302144930.html
SOURCE Technavio